A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety

被引:97
作者
Griebel, G
Perrault, G
Sanger, DJ
机构
[1] CNS Research Department, Synthélabo Recherche, 92220 Bagneux, 31, avenue Paul Vaillant-Couturier
关键词
mianserin; SE; 206553; MDL 100,907; 5-HT2 receptor antagonists; anxiety; Vogel drinking test; elevated plus-maze; mouse defense test battery (MDTB); light/dark choice test;
D O I
10.1016/S0028-3908(97)00034-8
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Although there is some evidence that compounds acting at 5-HT2 receptors show anxiolytic activity, little is known about the specific involvement of the different 5-HT2 receptor subtypes in the modulation of anxiety-related responses. In the present study, the behavioural effects of mianserin, a nonselective 5-HT2 receptor antagonist, MDL 100,907, a selective 5-HT2A receptor antagonist, and SE 206553, a selective 5-HT2B/2C receptor antagonist, were investigated in two rat (the Vogel drinking conflict and the elevated plus-maze tests) and two mouse (i.e. the mouse defense test battery (MDTB) and the light/dark choice test) models of anxiety. Diazepam was used as a positive control. In the Vogel drinking test, mianserin (10 mg/kg) and SB 206553 (3-30 mg/kg), but not MDL 100,907, increased punished responding. Similarly, mianserin (1 mg/kg) and SB 206553 (3-10 mg/kg), but not MDL 100,907, increased entries into the open arms of the elevated plus-maze. These effects are consistent with anxiolytic-like actions of mianserin and SE 206553, although the magnitude of the effects of these two compounds was less than those of diazepam. In addition, in the MDTB, the 5-HT2 antagonists did not clearly affect the defensive reactions of mice exposed to a rat stimulus and they failed to reverse the avoidance of the illuminated box in the light/dark choice test. These results indicate a lack of anxiolytic-like action of the compounds in mice. These behavioural profiles suggest that blockade of the 5-HT2A receptor may not reduce anxiety and demonstrate that 5-HT2B and/or 5-HT2C receptor subtypes may be primarily involved in the anxiolytic-like effects of mianserin and SE 206553 in rats. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:793 / 802
页数:10
相关论文
共 63 条
[1]   PROFILES OF INTERACTION OF R(+)/S(-)-ZACOPRIDE AND ANXIOLYTIC AGENTS IN A MOUSE MODEL [J].
BARNES, NM ;
CHENG, CHK ;
COSTALL, B ;
GE, J ;
KELLY, ME ;
NAYLOR, RJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 218 (01) :91-100
[2]   5-HT2 RECEPTOR SUBTYPES - A FAMILY RE-UNITED [J].
BAXTER, G ;
KENNETT, G ;
BLANEY, F ;
BLACKBURN, T .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (03) :105-110
[3]  
Baxter Gordon Smith, 1995, Behavioural Brain Research, V73, P149
[4]   PD135158, A CCK-B ANTAGONIST, REDUCES STATE, BUT NOT TRAIT ANXIETY IN MICE [J].
BELZUNG, C ;
PINEAU, N ;
BEUZEN, A ;
MISSLIN, R .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1994, 49 (02) :433-436
[5]   THE INFLUENCE OF RITANSERIN, A SEROTONIN ANTAGONIST, IN ANXIETY DISORDERS - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY VERSUS LORAZEPAM [J].
CEULEMANS, DLS ;
HOPPENBROUWERS, MLJA ;
GELDERS, YG ;
REYNTJENS, AJM .
PHARMACOPSYCHIATRY, 1985, 18 (05) :303-305
[6]   SEROTONIN FUNCTION IN ANXIETY .2. EFFECTS OF THE SEROTONIN AGONIST MCPP IN PANIC DISORDER PATIENTS AND HEALTHY-SUBJECTS [J].
CHARNEY, DS ;
WOODS, SW ;
GOODMAN, WK ;
HENINGER, GR .
PSYCHOPHARMACOLOGY, 1987, 92 (01) :14-24
[7]  
COLE JC, 1993, BEHAV PHARMACOL, V4, P573
[8]   ETHOLOGICAL EVALUATION OF THE EFFECTS OF ACUTE AND CHRONIC BUSPIRONE TREATMENT IN THE MURINE ELEVATED PLUS-MAZE TEST - COMPARISON WITH HALOPERIDOL [J].
COLE, JC ;
RODGERS, RJ .
PSYCHOPHARMACOLOGY, 1994, 114 (02) :288-296
[9]   BEHAVIORAL AND 5-HT ANTAGONIST EFFECTS OF RITANSERIN - A PURE AND SELECTIVE ANTAGONIST OF LSD DISCRIMINATION IN RAT [J].
COLPAERT, FC ;
MEERT, TF ;
NIEMEGEERS, CJE ;
JANSSEN, PAJ .
PSYCHOPHARMACOLOGY, 1985, 86 (1-2) :45-54
[10]   ACTIONS OF BUSPIRONE IN A PUTATIVE MODEL OF ANXIETY IN THE MOUSE [J].
COSTALL, B ;
KELLY, ME ;
NAYLOR, RJ ;
ONAIVI, ES .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1988, 40 (07) :494-500